tolmar | fensolvi® (leuprolide acetate) for injectable suspension

An Educational Program Designed For Pediatric Healthcare Professionals

# Beyond the Diagnosis: Compassionate Care for Children with Central Precocious Puberty



**Program Objectives:**

- ✓ Understand and discuss central precocious puberty (CPP)
  - Diagnostic criteria
  - Treatment goals
- ✓ Discuss the role nurses play in treatment decisions and elevating the voice of a child with CPP and their caregivers in these discussions
- ✓ Examine the use, mixing, and administration of Fensolvi® for treating children with CPP
- ✓ Evaluate the available programs and resources developed by Tolmar that can support children with CPP, their caregivers, and their healthcare providers

**Program Length:** 45-60 minutes

**Where:** Your clinic or a location of your choosing (during work or after hours)

**Presented by:** A licensed trained nurse.
See reverse for more details →

## Schedule an in-person or virtual presentation

**CONTACT**

**Pete McAdams**
Director Strategic Partnerships, Tolmar
pete.mcadams@tolmar.com
615-481-1219

**IMPORTANT SAFETY INFORMATION FOR FENSOLVI**

FENSOLVI (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist used to treat patients 2 years of age and older with central precocious puberty (CPP). CPP may be diagnosed when signs of sexual maturity begin to develop in girls under the age of 8 or in boys under the age of 9.

FENSOLVI is contraindicated in individuals with hypersensitivity to any drug that is in the same class as FENSOLVI, in individuals who are allergic to any of the ingredients in FENSOLVI, or in individuals who are pregnant. FENSOLVI may cause fetal harm when administered to a pregnant patient.

**See additional Important Safety Information on reverse side.**

An Educational Program Designed For Pediatric Healthcare Professionals

This program is delivered by a licensed trained nurse with extensive clinical experience with Fensolvi®


## Program Presenters:

- **Christine Anderson RN**, BSN
  Ann & Robert H Lurie Children's Hospital
  Chicago, IL
- **Mary Bertossi**, CPNP
  Van Meter Pediatric Endocrinology
  Atlanta, GA
- **Cheryl Lucas**, RN, BSN, CPN
  WakeMed Pediatric Endocrinology and Pediatric Cardiology
  Raleigh, NC
- **Amanda Patterson**, RN, CDCES, MSN
  INTEGRIS Health Pediatric Endocrinology
  Oklahoma City, OK
- **Kristin Sabanosh,** MSN, APN, CPNP, CDCES
  Atlantic Health Services Morristown Medical Center
  Morristown, NJ

## Schedule an in-person or virtual presentation

CONTACT

**Pete McAdams**
Director Strategic Partnerships, Tolmar
pete.mcadams@tolmar.com
615-481-1219




**IMPORTANT SAFETY INFORMATION FOR FENSOLVI** (continued)

During the first few weeks of treatment, increases in gonadotropins and sex steroids above baseline may result in an increase in signs and symptoms of puberty including vaginal bleeding in girls.

Psychiatric events have been reported in patients taking GnRH agonists. Events include emotional lability, such as crying, irritability, impatience, anger, and aggression. Patients should be monitored for development or worsening of psychiatric symptoms.

Convulsions have been observed in patients treated with GnRH agonists with or without a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs.

Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis, have occurred in patients receiving GnRH agonists. Monitor for and advise patients of the signs and symptoms of SCARs.

Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) has been reported in pediatric patients treated with GnRH agonists. Patients should be monitored for headache, papilledema and blurred vision.

The most common adverse events seen with FENSOLVI were: injection site pain, nasopharyngitis, pyrexia, headache, cough, abdominal pain, injection site erythema, nausea, constipation, vomiting, upper respiratory tract infection, bronchospasm, productive cough and hot flush.

**Please see full Prescribing Information for more information at Fensolvi.com/hcp**

© 2026 Tolmar, Inc. All rights reserved. Tolmar, Fensolvi and their associated logos are trademarks of the Tolmar Group. Third-party trademarks and product names belong to their respective owners. TPI.2025.eng.4901.v4 03/26